Metabolic positron emission tomography imaging in cancer detection and therapy response

Seminars in Oncology

Volumn 38, Issue 1, 2011, Pages 55-69

  Zhu, Aizhi ^a   Lee, Daniel ^a   Shim, Hyunsuk ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FLUOROETHYL)TYROSINE F 18; 6 FLUORODOPA F 18; ALPHA METHYL TYROSINE F 18; AMINO ACID DERIVATIVE; ANTI 1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID F 18; ANTINEOPLASTIC AGENT; CHOLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROTYROSINE F 18; GLUCOSE; HISTIDINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; ISOLEUCINE; LEUCINE; LIPID; METHIONINE; PHENYLALANINE; RADIOPHARMACEUTICAL AGENT; TAXANE DERIVATIVE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; VALINE;

ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG TUMOR LEVEL; DRUG UPTAKE; ESOPHAGUS CANCER; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; LIPOGENESIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; SARCOMA; SENSITIVITY AND SPECIFICITY; TESTIS CANCER; THYROID CANCER; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; UTERINE CERVIX CANCER;

CHOLINE; DRUG MONITORING; FLUORODEOXYGLUCOSE F18; HUMANS; MOLECULAR IMAGING; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TYROSINE;

EID: 79952159653     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.11.012     Document Type: Article

References (117)

1. D.W. Townsend, and T. Beyer A combined PET/CT scanner: the path to true image fusion Br J Radiol 75 Spec No 2002 S24 S30
2. T.M. Blodgett, C.C. Meltzer, and D.W. Townsend PET/CT: form and function Radiology 242 2007 360 385 (Pubitemid 46150968)
3. E.M. Rohren, T.G. Turkington, and R.E. Coleman Clinical applications of PET in oncology Radiology 231 2004 305 332 (Pubitemid 38552885)
4. P. Som, H.L. Atkins, and D. Bandoypadhyay A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection J Nucl Med 21 1980 670 675 (Pubitemid 10034639)
5. G.L. Semenza, B.H. Jiang, and S.W. Leung Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1 J Biol Chem 271 1996 32529 32537
6. G.L. Semenza, P.H. Roth, H.M. Fang, and G.L. Wang Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1 J Biol Chem 269 1994 23757 23763 (Pubitemid 24293585)
7. H. Shim, Y.S. Chun, B.C. Lewis, and C.V. Dang A unique glucose-dependent apoptotic pathway induced by c-Myc Proc Natl Acad Sci U S A 95 1998 1511 1516 (Pubitemid 28103423)
8. H. Shim, C. Dolde, and B.C. Lewis c-Myc transactivation of LDH-A: implications for tumor metabolism and growth Proc Natl Acad Sci U S A 94 1997 6658 6663 (Pubitemid 27281920)
9. R.C. Osthus, H. Shim, and S. Kim Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc J Biol Chem 275 2000 21797 21800 (Pubitemid 30621745)
10. P.L. Pedersen Tumor mitochondria and the bioenergetics of cancer cells Prog Exp Tumor Res 22 1978 190 274
11. M.E. Juweid, and B.D. Cheson Positron-emission tomography and assessment of cancer therapy N Engl J Med 354 2006 496 507 (Pubitemid 43200300)
12. Medicare National Coverage determinations manual c, part 4 (sections 200 - 310.1) Coverage determinations 220.6 positron emission tomography (PET) scans (effective April 3, 2009) http://www.cms.hhs.gov/transmittals/downloads/R108NCD. pdf
13. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
14. W.J. Oyen, J. Bussink, A.F. Verhagen, F.H. Corstens, and G.P. Bootsma Role of FDG-PET in the diagnosis and management of lung cancer Expert Rev Anticancer Ther 4 2004 561 567 (Pubitemid 39161989)
15. 18F-FDG PET in a coincidence technique (hybrid PET) Nucl Med Commun 24 2003 37 45
16. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification J Nucl Med 42 2001 1605 1613 (Pubitemid 33131318)
17. 18F-FDG PET in assessment of response in non-small cell lung cancer J Nucl Med 50 Suppl 1 2009 31S 42S
18. P. Verboom, H. van Tinteren, and O.S. Hoekstra Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study Eur J Nucl Med Mol Imaging 30 2003 1444 1449 (Pubitemid 37356109)
19. S.N. Reske, and J. Kotzerke FDG-PET for clinical use Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000 Eur J Nucl Med 28 2001 1707 1723 (Pubitemid 33036116)
20. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer Eur J Nucl Med Mol Imaging 34 2007 463 471 (Pubitemid 46426996)
21. J. Gauger, E.F. Patz Jr, R.E. Coleman, and J.E. Herndon 2nd Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence J Thorac Oncol 2 2007 499 505 (Pubitemid 47171803)
22. D. Hellwig, A. Groschel, and T.P. Graeter Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer Eur J Nucl Med Mol Imaging 33 2006 13 21 (Pubitemid 41785304)
23. M. Tulchinsky, S. Coquia, and H. Wagner Jr Small bowel metastasis from lung cancer detected on FDG PET/CT Clin Nucl Med 34 2009 446 448
24. N. Liu, N.L. Ma, and N.W. Zhou Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT Eur J Radiol 74 2010 231 235
25. Y. Yamamoto, R. Kameyama, M. Murota, S. Bandoh, T. Ishii, and Y. Nishiyama Early assessment of therapeutic response using FDG PET in small cell lung cancer Mol Imaging Biol 11 2009 467 472
26. N. Sunaga, N. Oriuchi, and K. Kaira Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer Lung Cancer 59 2008 203 210 (Pubitemid 351173409)
27. 18F-FDG PET in patients with non-small cell lung cancer J Nucl Med 48 2007 1592 1598 (Pubitemid 47572705)
28. D. Lardinois, W. Weder, and T.F. Hany Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography N Engl J Med 348 2003 2500 2507 (Pubitemid 36706537)
29. M. Basely Jr., P. Bernard, O. Gisserot, P. Maszelin, E. Bussy, and J.P. de Jaureguiberry Umbilical metastasis from breast cancer detected by FDG PET Clin Nucl Med 34 2009 292 293
30. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer Eur J Nucl Med Mol Imaging 36 2009 1551 1557
31. T.S. Aukema, M.E. Straver, R.A. Valdes Olmos, and W.V. Vogel A different role for FDG PET/CT in axillary lymph node staging in breast cancer Eur J Nucl Med Mol Imaging 36 2009 1896 1897
32. N.R. Peare, N.R.T. Staff, and N.S.D. Heys The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature Breast Cancer Res Treat 123 2010 281 290
33. O. Belohlavek What is the role of FDG-PET in the initial staging of breast cancer? Eur J Nucl Med Mol Imaging 35 2008 472 474
34. T.F. ermik, A. Mavi, S. Basu, and A. Alavi Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer Eur J Nucl Med Mol Imaging 35 2008 475 483 (Pubitemid 351661670)
35. F. Crippa, A. Gerali, A. Alessi, R. Agresti, and E. Bombardieri FDG-PET for axillary lymph node staging in primary breast cancer Eur J Nucl Med Mol Imaging 31 Suppl 1 2004 S97 S102
36. J.S. Sloka, P.D. Hollett, and M. Mathews A quantitative review of the use of FDG-PET in the axillary staging of breast cancer Med Sci Monit 13 2007 RA37 RA46
37. 18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer BMC Cancer 8 2008 165
38. N.M.E. Straver, N.T.S. Aukema, and N.R.A. Olmos Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients Eur J Nucl Med Mol Imaging 37 2010 1069 1076
39. 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur Radiol 19 2009 1347 1357
40. N. Momiyama, T. Ishikawa, Y. Ichikawa, H. Shimada, A. Katayama, and Y. Ozawa Early prediction of response to primary chemotherapy by sequential FDG -PET in patients with advanced breast cancer Nippon Rinsho 65 Suppl 6 2007 385 388
41. K. Kitajima, K. Murakami, and E. Yamasaki Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT Eur J Nucl Med Mol Imaging 36 2009 1388 1396
42. 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan Hepatogastroenterology 53 2006 348 350
43. J. Votrubova, O. Belohlavek, and M. Jaruskova The role of FDG-PET/CT in the detection of recurrent colorectal cancer Eur J Nucl Med Mol Imaging 33 2006 779 784 (Pubitemid 43979685)
44. C. Ferme, H. Eghbali, and J.H. Meerwaldt Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease N Engl J Med 357 2007 1916 1927 (Pubitemid 350074687)
45. M.E. Juweid Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma Hematology Am Soc Hematol Educ Program 2006 259 265 510-1
46. T. Kazama, S.C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H.A. Macapinlac FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls Radiographics 25 2005 191 207 (Pubitemid 40186951)
47. R. Kumar, Y. Xiu, A. Mavi, G. El-Haddad, H. Zhuang, and A. Alavi FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature Clin Nucl Med 30 2005 222 230 (Pubitemid 40396815)
48. A. Al-Ibraheem, A. Buck, B.J. Krause, K. Scheidhauer, and M. Schwaiger Clinical applications of FDG PET and PET/CT in head and neck cancer J Oncol 2009 article ID 208725
49. M. Machtay, M. Natwa, and J. Andrel Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer Head Neck 31 2009 195 201
50. R.J. Wong Current status of FDG-PET for head and neck cancer J Surg Oncol 97 2008 649 652 (Pubitemid 351812964)
51. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis J Natl Cancer Inst 100 2008 712 720
52. B.F. Branstetter, T.M. Blodgett, and L.A. Zimmer Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 235 2005 580 586 (Pubitemid 40571100)
53. M.B. Fukui, T.M. Blodgett, and C.C. Meltzer PET/CT imaging in recurrent head and neck cancer Semin Ultrasound CT MR 24 2003 157 163 (Pubitemid 36818819)
54. B.D. Nguyen, P.C. Ram, and M.C. Roarke Endotracheal metastasis from squamous cell cancer of the head and neck: PET/CT imaging Clin Nucl Med 33 2008 340 341 (Pubitemid 351589528)
55. 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus J Nucl Med 48 2007 1251 1258 (Pubitemid 47242789)
56. B. Klaeser, E. Nitzsche, and J.C. Schuller Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02) Onkologie 32 2009 724 730
57. T. Isa, T. Kaneshiro, and H. Yamamoto Case of esophageal cancer successfully performed in early response evaluation for preoperative chemotherapy by FDG-PET Nippon Shokakibyo Gakkai Zasshi 105 2008 1193 1199
58. 18F-FDG-PET in therapy response of esophageal cancer Radiologe 47 2007 110 114
59. 18F-FDG PET/CT for assessing response to therapy in esophageal cancer J Nucl Med 50 Suppl 1 2009 89S 96S
60. N.A.A. Mansour 3rd, N.M.C. Kelley, N.A.R. Hatmaker, N.G.E. Holt, and N.H.S. Schwartz Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging Ann Surg Oncol 17 2010 1144 1151
61. K. Strobel, R. Dummer, D.B. Husarik, M. Perez Lago, T.F. Hany, and H.C. Steinert High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases Radiology 244 2007 566 574 (Pubitemid 47080890)
62. 18FDG-PET-scan in staging of primary malignant melanoma of the oesophagus: a case report Acta Gastroenterol Belg 69 2006 12 14
63. 18F-FDG PET in cutaneous melanoma Eur J Nucl Med Mol Imaging 37 2010 284 300
64. F. Crippa, M. Leutner, and F. Belli Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma J Nucl Med 41 2000 1491 1494
65. J.D. Wagner, D.S. Schauwecker, D. Davidson, S. Wenck, S.H. Jung, and G. Hutchins FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume J Surg Oncol 77 2001 237 242 (Pubitemid 32744191)
66. 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer J Nucl Med 49 2008 1408 1413
67. 18F-FDG PET than by CT J Gastrointest Surg 14 2010 131 140
68. J. Lachter, A.C. Adler, Z. Keidar, and R. Haddad FDG-PET/CT identifies a curable pancreatic cancer surgical tract metastasis after failure by other imaging modalities Isr Med Assoc J 10 2008 243 244 (Pubitemid 351649630)
69. Y. Nishiyama, Y. Yamamoto, and K. Yokoe Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer Ann Nucl Med 19 2005 491 497 (Pubitemid 41531270)
70. Y. Mataki, H. Shinchi, and H. Kurahara Clinical usefulness of FDG-PET for pancreatic cancer Gan To Kagaku Ryoho 36 2009 2516 2520
71. T. Higashi, T. Saga, and Y. Nakamoto Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)usefulness and limitations in "clinical reality" Ann Nucl Med 17 2003 261 279 (Pubitemid 37012038)
72. 18FDG uptake in brown fat: potential for false positives Radiol Technol 78 2007 361 366
73. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits J Nucl Med 47 2006 1351 1358 (Pubitemid 47544891)
74. 18F-FDG for differentiating tumor from inflammation in a rodent model J Nucl Med 45 2004 695 700 (Pubitemid 47618601)
75. H.N. Christensen Role of amino acid transport and countertransport in nutrition and metabolism Physiol Rev 70 1990 43 77 (Pubitemid 20037281)
76. O. Yanagida, Y. Kanai, and A. Chairoungdua Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines Biochim Biophys Acta 1514 2001 291 302 (Pubitemid 32831016)
77. K. Nakanishi, S. Ogata, and H. Matsuo Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract Virchows Arch 451 2007 681 690 (Pubitemid 47340986)
78. H. Kobayashi, Y. Ishii, and T. Takayama Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma J Surg Oncol 90 2005 233 238 (Pubitemid 40770938)
79. K. Kaira, N. Oriuchi, and H. Imai l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms Cancer Sci 99 2008 2380 2386
80. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas Mol Imaging Biol 10 2008 1 18
81. S. Leskinen-Kallio, K. Nagren, P. Lehikoinen, U. Ruotsalainen, M. Teras, and H. Joensuu Carbon-11-methionine and PET is an effective method to image head and neck cancer J Nucl Med 33 1992 691 695
82. T. Inoue, E.E. Kim, and F.C. Wong Comparison of fluorine-18- fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors J Nucl Med 37 1996 1472 1476 (Pubitemid 26321625)
83. 11C]methionine Eur J Nucl Med Mol Imaging 30 2003 1561 1567 (Pubitemid 37356125)
84. P. Lindholm, S. Leskinen, and K. Nagren Carbon-11-methionine PET imaging of malignant melanoma J Nucl Med 36 1995 1806 1810
85. O. Couturier, A. Luxen, J.F. Chatal, J.P. Vuillez, P. Rigo, and R. Hustinx Fluorinated tracers for imaging cancer with positron emission tomography Eur J Nucl Med Mol Imaging 31 2004 1182 1206 (Pubitemid 39050187)
86. P. Laverman, O.C. Boerman, F.H. Corstens, and W.J. Oyen Fluorinated amino acids for tumour imaging with positron emission tomography Eur J Nucl Med Mol Imaging 29 2002 681 690 (Pubitemid 34439330)
87. J. McConathy, and M.M. Goodman Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography Cancer Metastasis Rev 27 2008 555 573
88. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47 2006 393 403 (Pubitemid 46768480)
89. F. Thiele, J. Ehmer, and M.D. Piroth The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma Phys Med Biol 54 2009 5525 5539
90. 18F-fluoroethyl)-L- tyrosine PET and proton magnetic resonance spectroscopic imaging J Nucl Med 49 2008 721 729 (Pubitemid 351717536)
91. 18F-fluoroethyl-L: -tyrosine PET and magnetic resonance diffusion tensor imaging Acta Neurochir (Wien) 151 2009 1061 1069
92. M. Tripathi, R. Sharma, and M. D'Souza Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas Clin Nucl Med 34 2009 878 883
93. J.N. Talbot, K. Kerrou, F. Montravers, V. Nataf, and Y. Chevalme FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines Eur J Nucl Med Mol Imaging 34 2007 1131 1132 (Pubitemid 46919559)
94. 18F-FDG PET and evaluation of diagnostic accuracy J Nucl Med 47 2006 904 911 (Pubitemid 46939941)
95. 18F-FDOPA kinetics in brain tumors J Nucl Med 48 2007 1651 1661 (Pubitemid 47572713)
96. 18F-DOPA PET: a prospective, diagnostic accuracy study Lancet Oncol 7 2006 728 734 (Pubitemid 44283659)
97. 18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors J Nucl Med 40 1999 331 338 (Pubitemid 29077098)
98. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma J Nucl Med 48 2007 56 63 (Pubitemid 47555376)
99. 18F]FACBC) with PET in renal carcinoma Mol Imaging Biol 11 2009 434 438
100. M. Yoshimoto, A. Waki, A. Obata, T. Furukawa, Y. Yonekura, and Y. Fujibayashi Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate Nucl Med Biol 31 2004 859 865 (Pubitemid 39297683)
101. 18F- fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging J Nucl Med 43 2002 187 199 (Pubitemid 34151041)
102. 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors Eur J Nucl Med Mol Imaging 31 2004 1064 1072 (Pubitemid 39050172)
103. 18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer Ann Nucl Med 23 2009 541 548
104. 11C-choline PET/CT for detection of bone metastases Radiology 249 2008 1017 1025
105. T. Hara, N. Kosaka, and H. Kishi PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 1998 990 995 (Pubitemid 28270113)
106. 18F-FDG PET imaging in brain tumours Nucl Med Commun 29 2008 354 358 (Pubitemid 351644384)
107. 11C]choline J Nucl Med 38 1997 842 847 (Pubitemid 27251970)
108. T. Ohtani, H. Kurihara, and S. Ishiuchi Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging Eur J Nucl Med 28 2001 1664 1670 (Pubitemid 33036109)
109. X. Li, Q. Liu, and M. Wang C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions Clin Nucl Med 33 2008 671 676
110. 11C]Choline as a potential PET marker for imaging of breast cancer athymic mice Nucl Med Biol 29 2002 803 807 (Pubitemid 35346900)
111. 18F-FDG PET Ann Nucl Med 18 2004 409 417 (Pubitemid 39265062)
112. 11C]-acetate and [N-methyl-11C]-choline Q J Nucl Med Mol Imaging 53 2009 144 156
113. N.M. Beheshti, N.R. Vali, and N.P. Waldenberger The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT Mol Imaging Biol 11 2009 446 454
114. 18F] fluoroethylcholine for PET prostate cancer imaging Nucl Med Biol 36 2009 569 574
115. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 2009 122S 150S
116. D.A. Mankoff, A.F. Shields, and K.A. Krohn PET imaging of cellular proliferation Radiol Clin North Am 43 2005 153 167 (Pubitemid 40326566)
117. T. Barwick, B. Bencherif, J.M. Mountz, and N. Avril Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation Nucl Med Commun 30 2009 908 917